Drug Profile
Research programme: aurora kinase inhibitors - Bicoll GmbH
Alternative Names: Aurora kinase inhibitors - Bicoll/European Molecular Biology Laboratory (EMBL)Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Bicoll GmbH
- Developer Bicoll GmbH; European Molecular Biology Laboratory
- Class Small molecules
- Mechanism of Action Aurora kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in Germany
- 29 Jun 2010 Early research in Cancer in Germany (unspecified route)